AU3725689A - Expression of retrovirus gag protein in eukaryotic cells - Google Patents

Expression of retrovirus gag protein in eukaryotic cells

Info

Publication number
AU3725689A
AU3725689A AU37256/89A AU3725689A AU3725689A AU 3725689 A AU3725689 A AU 3725689A AU 37256/89 A AU37256/89 A AU 37256/89A AU 3725689 A AU3725689 A AU 3725689A AU 3725689 A AU3725689 A AU 3725689A
Authority
AU
Australia
Prior art keywords
expression
eukaryotic cells
gag protein
retrovirus gag
retrovirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU37256/89A
Other versions
AU627465B2 (en
Inventor
Dirk Gheysen
Eric Jacobs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
SmithKline Biological SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA, SmithKline Biological SA filed Critical GlaxoSmithKline Biologicals SA
Publication of AU3725689A publication Critical patent/AU3725689A/en
Application granted granted Critical
Publication of AU627465B2 publication Critical patent/AU627465B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
AU37256/89A 1988-06-03 1989-06-30 Expression of retrovirus gag protein in eukaryotic cells Ceased AU627465B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20227188A 1988-06-03 1988-06-03

Publications (2)

Publication Number Publication Date
AU3725689A true AU3725689A (en) 1991-01-03
AU627465B2 AU627465B2 (en) 1992-08-27

Family

ID=22749175

Family Applications (2)

Application Number Title Priority Date Filing Date
AU37256/89A Ceased AU627465B2 (en) 1988-06-03 1989-06-30 Expression of retrovirus gag protein in eukaryotic cells
AU43206/89A Abandoned AU4320689A (en) 1988-06-03 1989-07-11 Expression of retrovirus gag protein in eukaryotic cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU43206/89A Abandoned AU4320689A (en) 1988-06-03 1989-07-11 Expression of retrovirus gag protein in eukaryotic cells

Country Status (8)

Country Link
EP (1) EP0345242A3 (en)
AP (1) AP129A (en)
AU (2) AU627465B2 (en)
IL (1) IL90381A0 (en)
NZ (1) NZ229297A (en)
PT (1) PT90731A (en)
WO (1) WO1991000904A1 (en)
ZA (1) ZA894137B (en)

Families Citing this family (258)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2003794C (en) * 1988-12-01 2000-02-08 Hanne R. Johansen Expression of hiv proteins in drosophila cells
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US5786464C1 (en) * 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6592877B1 (en) 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6290969B1 (en) 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6534312B1 (en) 1996-02-22 2003-03-18 Merck & Co., Inc. Vaccines comprising synthetic genes
JP4383530B2 (en) 1996-04-05 2009-12-16 ノバルティス バクシンズ アンド ダイアグノスティックス， インコーポレーテッド Alphavirus vectors with reduced inhibition of cellular macromolecular synthesis
EP0935659A1 (en) 1996-09-17 1999-08-18 Chiron Corporation Compositions and methods for treating intracellular diseases
US6114148C1 (en) * 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
AU743616B2 (en) * 1997-02-07 2002-01-31 Merck & Co., Inc. Synthetic HIV gag genes
US6696291B2 (en) 1997-02-07 2004-02-24 Merck & Co., Inc. Synthetic HIV gag genes
US6261562B1 (en) 1997-02-25 2001-07-17 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
AU8692598A (en) 1997-08-04 1999-02-22 Calydon, Inc. A human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereof
CN1263854C (en) 1997-11-06 2006-07-12 启龙股份公司 Neisserial antigens
US6914131B1 (en) 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
WO1999033869A2 (en) 1997-12-24 1999-07-08 Corixa Corporation Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
DK1047784T4 (en) 1998-01-14 2015-06-15 Novartis Vaccines & Diagnostic NEISSERA meningitidis ANTIGENS
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
EP1792988A3 (en) 1998-03-18 2007-08-22 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
PT1645631E (en) 1998-05-01 2008-02-04 Novartis Vaccines & Diagnostic Neisseria antigens and compositions
EP1102790B1 (en) 1998-08-07 2014-05-07 University of Washington Immunological Herpes Simplex Virus antigens and methods for use thereof
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
EP1121437B1 (en) 1998-10-15 2008-02-20 Novartis Vaccines and Diagnostics, Inc. Metastatic breast and colon cancer regulated genes
CA2746535A1 (en) 1998-12-08 2000-06-15 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
ATE519840T1 (en) 1998-12-16 2011-08-15 Novartis Vaccines & Diagnostic HUMAN CYCLIN DEPENDENT KINASE (HPNQALRE)
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
JP2002533124A (en) 1998-12-31 2002-10-08 カイロン コーポレイション Improved expression of HIV polypeptide and generation of virus-like particles
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US7625859B1 (en) 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
JP2002543769A (en) 1999-04-02 2002-12-24 コリクサ コーポレイション Compounds and methods for treatment and diagnosis of lung cancer
US8143386B2 (en) 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
NZ581940A (en) 1999-04-30 2011-07-29 Novartis Vaccines & Diagnostic Conserved neisserial antigens
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
WO2001024820A1 (en) 1999-10-07 2001-04-12 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
CA2864069A1 (en) 1999-10-29 2001-05-03 Novartis Vaccines And Diagnostics S.R.L. Neisserial antigenic peptides
ATE446365T1 (en) 1999-11-18 2009-11-15 Novartis Vaccines & Diagnostic HUMAN FGF-21 GENE AND GENE EXPRESSION PRODUCTS
EP2281571A3 (en) 2000-01-17 2012-04-25 Novartis Vaccines and Diagnostics S.r.l. Outer membrane vesicle (omv) vaccine comprising n. meningitidids serogroup b outer membrane proteins
EP1854476A3 (en) 2000-02-09 2008-05-07 Bas Medical, Inc. Use of relaxin to treat diseases related to vasoconstriction
PT1265915E (en) 2000-02-23 2011-02-07 Glaxosmithkline Biolog Sa Novel compounds
WO2001062893A2 (en) 2000-02-25 2001-08-30 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
RU2299906C2 (en) 2000-02-28 2007-05-27 Новартис Вэксинс Энд Диагностикс С.Р.Л. Heterologous expression of neisseria proteins
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
EP2075255A1 (en) 2000-03-08 2009-07-01 Novartis Vaccines and Diagnostics, Inc. Human FGF-23 gene and gene expression products
US20030175700A1 (en) 2000-04-21 2003-09-18 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
DE60134134D1 (en) 2000-05-19 2008-07-03 Corixa Corp PROPHYLACTIC AND THERAPEUTIC TREATMENT OF TEN WITH COMPOUNDS BASED ON MONOSACCHARIDES
EP1950297A2 (en) 2000-05-31 2008-07-30 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
ES2398391T3 (en) 2000-06-15 2013-03-15 Novartis Vaccines And Diagnostics, Inc. Polynucleotides related to colon cancer
ATE442866T1 (en) 2000-06-20 2009-10-15 Corixa Corp FUSION PROTEINS FROM MYCOBACTERIUM TUBERCULOSIS
ATE396265T1 (en) 2000-06-28 2008-06-15 Corixa Corp COMPOSITIONS AND METHODS FOR THERAPY AND DIAGNOSIS OF LUNG CANCER
US20020165192A1 (en) 2000-09-19 2002-11-07 Kerr William G. Control of NK cell function and survival by modulation of ship activity
US7691821B2 (en) 2001-09-19 2010-04-06 University Of South Florida Inhibition of SHIP to enhance stem cell harvest and transplantation
EP2284183A1 (en) 2000-10-27 2011-02-16 Novartis Vaccines and Diagnostics S.r.l. Nucleic acids and proteins from streptococcus groups A and B
WO2002046477A2 (en) 2000-12-07 2002-06-13 Chiron Corporation Endogenous retroviruses up-regulated in prostate cancer
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
AU2002303261A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
WO2002081642A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
WO2002081641A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
WO2002089747A2 (en) 2001-05-09 2002-11-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
WO2003004620A2 (en) 2001-07-05 2003-01-16 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
CA2452119C (en) 2001-07-05 2013-10-15 Chiron Corporation Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof
US7498407B2 (en) 2001-11-09 2009-03-03 Georgetown University Vascular endothelial cell growth inhibitor, VEGI-192a
EP2335724A1 (en) 2001-12-12 2011-06-22 Novartis Vaccines and Diagnostics S.r.l. Immunisation against chlamydia trachomatis
ES2405790T3 (en) 2001-12-17 2013-06-03 Corixa Corporation Compositions and methods for therapy and diagnosis of inflammatory bowel disease
DE60326931D1 (en) 2002-01-08 2009-05-14 Novartis Vaccines & Diagnostic DIFFERENTIALLY EXPRESSED GENEVA PRODUCTS AND THEIR USE PROCEDURES IN CANNULAR MAMMA CELLS
WO2003070187A2 (en) 2002-02-15 2003-08-28 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
IL163988A0 (en) 2002-03-15 2005-12-18 Wyeth Corp Mutants of the p4 protein of nontypable haemophilus influenzae with reduced enzymatic activity
CA2479730A1 (en) 2002-03-21 2003-10-02 Sagres Discovery, Inc. Novel compositions and methods in cancer
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
US7138512B2 (en) 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
US20030206916A1 (en) 2002-05-03 2003-11-06 Rush-Presbyterian-St. Luke's Medical Center Immunogenic peptides
AU2003276679A1 (en) 2002-06-13 2003-12-31 Chiron Corporation Vectors for expression of hml-2 polypeptides
EP2865386B1 (en) 2002-07-18 2017-07-05 University of Washington Pharmaceutical compositions comprising immunologically active herpes simplex virus (HSV) protein fragments
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
CA2511598C (en) 2002-12-24 2016-09-13 Rinat Neuroscience Corp. Anti-ngf antibodies and methods using same
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
BRPI0406628A (en) 2003-01-06 2005-12-06 Corixa Corp Certain aminoalkyl glucosaminide phosphate compounds and their use
JP2007524362A (en) 2003-02-14 2007-08-30 サイグレス ディスカバリー， インコーポレイテッド Therapeutic GPCR targets in cancer
US7767387B2 (en) 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
US20040170982A1 (en) 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
CA2516454A1 (en) 2003-02-19 2004-09-02 Rinat Neuroscience Corp. Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
US20070178066A1 (en) 2003-04-21 2007-08-02 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
EP1619951B1 (en) 2003-04-21 2011-06-22 Epeius Biotechnologies Corporation Methods and compositions for treating disorders
WO2005007673A2 (en) 2003-07-03 2005-01-27 Rush University Medical Center Immunogenic peptides
US7807646B1 (en) 2003-11-20 2010-10-05 University Of South Florida SHIP-deficiency to increase megakaryocyte progenitor production
US7763592B1 (en) 2003-11-20 2010-07-27 University Of South Florida SHIP-deficiency to increase megakaryocyte progenitor production
EP1700121A4 (en) 2003-12-23 2008-09-03 Rinat Neuroscience Corp Agonist anti-trkc antibodies and methods using same
DK1736541T3 (en) 2004-03-29 2013-05-06 Galpharma Co Ltd Newly modified galectin 9 protein and its use
ES2338344T3 (en) 2004-04-07 2010-05-06 Rinat Neuroscience Corporation PROCESS OF BONE CANCER TREATMENT THROUGH THE ADMINISTRATION OF AN ANTAGONIST OF THE NEURONAL GROWTH FACTOR.
EP1789805B1 (en) 2004-07-14 2010-09-15 The Regents of The University of California Biomarker for early detection of ovarian cancer
US20060024677A1 (en) 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
US7927594B2 (en) 2004-07-30 2011-04-19 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide
AU2005272920B2 (en) 2004-08-10 2011-05-12 Institute For Multiple Myeloma And Bone Cancer Research Methods of regulating differentiation and treating of multiple myeloma
EP2305294B1 (en) 2004-09-22 2015-04-01 GlaxoSmithKline Biologicals SA Immunogenic composition for use in vaccination against staphylococcei
NZ580974A (en) 2005-02-18 2011-05-27 Novartis Vaccines & Diagnostic Immunogens from uropathogenic escherichia coli
EP1701165A1 (en) 2005-03-07 2006-09-13 Johannes Dr. Coy Therapeutic and diagnostic uses of TKTL1 and inhibitors and activators thereof
EP2392347A3 (en) 2005-03-31 2012-01-18 GlaxoSmithKline Biologicals S.A. Vaccines against chlamydial infection
US20090214536A1 (en) 2005-04-07 2009-08-27 Guoying Yu CACNA1E in Cancer Diagnosis, Detection and Treatment
EP1871911A2 (en) 2005-04-07 2008-01-02 Chiron Corporation Cancer-related genes (prlr)
UY29504A1 (en) 2005-04-29 2006-10-31 Rinat Neuroscience Corp DIRECTED ANTIBODIES AGAINST BETA AMYLOID PEPTIDE AND METHODS USING THE SAME.
CN101273055B (en) 2005-04-29 2016-03-16 葛兰素史密丝克莱恩生物有限公司 For preventing or treat the novel method of m tuberculosis infection
CN101282994B (en) 2005-07-22 2013-09-18 Y's治疗有限公司 Anti-CD26 antibodies and methods of use thereof
PT2380592T (en) 2005-11-14 2018-06-06 Teva Pharmaceuticals Int Gmbh Antagonist antibody directed against calcitonin gene-related peptide
US20090081157A1 (en) 2006-01-09 2009-03-26 Richard Syd Kornbluth Immunostimulatory Combinations for Vaccine Adjuvants
EP1981905B1 (en) 2006-01-16 2016-08-31 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Chlamydia vaccine
EP1988920A1 (en) 2006-02-02 2008-11-12 Rinat Neuroscience Corp. Methods for treating obesity by administering a trkb antagonist
EP2010226B1 (en) 2006-04-07 2014-01-15 The Research Foundation of State University of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
TWI429658B (en) 2006-06-07 2014-03-11 Bioalliance Cv Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
EP2035035A2 (en) 2006-06-09 2009-03-18 Novartis AG Immunogenic compositions for streptococcus agalactiae
EP2586790A3 (en) 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
US8673859B2 (en) 2007-03-20 2014-03-18 New York University GM-CSF cosmeceutical compositions and methods of use thereof
EP3061462B1 (en) 2007-07-02 2019-02-27 Etubics Corporation Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
US8591898B2 (en) 2007-12-17 2013-11-26 Pfizer Limited Treatment of interstitial cystitis
CN101918448A (en) 2007-12-18 2010-12-15 生物联合公司 Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
AU2009234389B2 (en) 2008-04-10 2014-08-21 Cell Signaling Technology, Inc. Compositions and methods for detecting EGFR mutations in cancer
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
TWI445716B (en) 2008-09-12 2014-07-21 Rinat Neuroscience Corp Pcsk9 antagonists
CA2738019A1 (en) 2008-09-23 2010-04-08 President And Fellows Of Harvard College Sirt4 and uses thereof
WO2010080985A1 (en) 2009-01-08 2010-07-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for induced brown fat differentiation
WO2010086828A2 (en) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
JP2012519482A (en) 2009-03-06 2012-08-30 ノバルティス アーゲー Chlamydia antigen
WO2010118243A2 (en) 2009-04-08 2010-10-14 Genentech, Inc. Use of il-27 antagonists to treat lupus
DK2510947T3 (en) 2009-04-14 2016-03-21 Glaxosmithkline Biolog Sa Compositions for Immunization against Staphylococcus aureus.
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
DK2464658T3 (en) 2009-07-16 2014-12-15 Novartis Ag Detoxified escherichia coli immunogens
US8563261B2 (en) 2009-09-28 2013-10-22 The Trustees Of The University Of Pennsylvania Method of diagnosing and treating interstitial cystitis
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
US20130040853A1 (en) 2010-01-21 2013-02-14 Dana-Farber Cancer Institute Inc. Context Specific Genetic Screen Platform to Aid in Gene Discovery and Target Validation
WO2011092253A1 (en) 2010-01-27 2011-08-04 Glaxosmithkline Biologicals S.A. Modified tuberculosis antigens
AR080291A1 (en) 2010-02-24 2012-03-28 Rinat Neuroscience Corp ANTI-BODIES ANTAGONISTS ANTI RECEIVER OF IL-7 AND PROCEDURES
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
KR20120138241A (en) 2010-03-11 2012-12-24 화이자 인코포레이티드 Antibodies with ph dependent antigen binding
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
WO2011133931A1 (en) 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
US8747844B2 (en) 2010-07-30 2014-06-10 Saint Louis University Methods of treating pain
US9539427B2 (en) 2010-11-08 2017-01-10 The Johns Hopkins University Methods for improving heart function
WO2012075243A2 (en) 2010-12-01 2012-06-07 The University Of North Carolina At Chapel Hill Methods and compositions for targeting sites of neovascular growth
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
WO2012154994A2 (en) 2011-05-10 2012-11-15 The Regents Of The University Of Californa A novel adenovirus isolated from titi monkeys
US10221218B2 (en) 2011-05-10 2019-03-05 The Regents Of The University Of California Adenovirus isolated from titi monkeys
CN103608030A (en) 2011-06-21 2014-02-26 昂科发克特公司 Compositions and methods for therapy and diagnosis of cancer
US20130071375A1 (en) 2011-08-22 2013-03-21 Saint Louis University Compositions and methods for treating inflammation
WO2013028527A1 (en) 2011-08-23 2013-02-28 Indiana University Research And Technology Corporation Compositions and methods for treating cancer
KR20140063747A (en) 2011-08-29 2014-05-27 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Use of hdl-related molecules to treat and prevent proinflammatory conditions
US10093705B2 (en) 2011-09-13 2018-10-09 Dana-Farber Cancer Institute, Inc. Compositions and methods for brown fat induction and activity using FNDC5
WO2013055911A1 (en) 2011-10-14 2013-04-18 Dana-Farber Cancer Institute, Inc. Znf365/zfp365 biomarker predictive of anti-cancer response
BR112014011331A2 (en) 2011-11-11 2017-04-25 Rinat Neuroscience Corp trop-2 specific antibodies and their uses
EP2794659A1 (en) 2011-12-22 2014-10-29 Rinat Neuroscience Corp. Human growth hormone receptor antagonist antibodies and methods of use thereof
WO2013093693A1 (en) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Staphylococcus aureus specific antibodies and uses thereof
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
BR112015010722A2 (en) 2012-11-09 2017-08-22 Pfizer SPECIFIC GROWTH FACTOR ANTIBODIES DERIVED FROM ISOFORM B PLATELETS AND COMPOSITIONS AND USES THEREOF
CA2902875A1 (en) 2013-03-14 2014-09-25 Epeius Biotechnologies Corporation Improved thymidine kinase gene
US9428537B2 (en) 2013-03-15 2016-08-30 The Board Of Trustees Of The Leland Stanford Junior University tRNA derived small RNAs (tsRNAs) involved in cell viability
MX371272B (en) 2013-03-15 2020-01-22 Univ California Mitochondrial-derived peptide mots3 regulates metabolism and cell survival.
AU2014240045A1 (en) 2013-03-15 2015-09-10 Dyax Corp. Anti-plasma kallikrein antibodies
CN105392882A (en) 2013-04-19 2016-03-09 加利福尼亚大学董事会 Lone star virus
SG11201508264UA (en) 2013-05-07 2015-11-27 Rinat Neuroscience Corp Anti-glucagon receptor antibodies and methods of use thereof
WO2014210546A1 (en) 2013-06-27 2014-12-31 University Of Washington Through Its Center For Commercialization Biocompatible polymeric system for targeted treatment of thrombotic and hemostatic disorders
US20160129017A1 (en) 2013-07-01 2016-05-12 The Research Foundation for the State University New York Ship inhibition to combat obesity
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
MX371455B (en) 2013-08-02 2020-01-28 Pfizer Anti-cxcr4 antibodies and antibody-drug conjugates.
KR102366076B1 (en) 2013-11-13 2022-02-21 화이자 인코포레이티드 Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
US9896502B2 (en) 2014-03-21 2018-02-20 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
EP3134546A4 (en) 2014-04-24 2017-12-06 Dana-Farber Cancer Institute, Inc. Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
WO2015168474A1 (en) 2014-04-30 2015-11-05 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
MX2016014824A (en) 2014-05-13 2017-03-23 Bioatla Llc Conditionally active biological proteins.
CA2986354A1 (en) 2014-06-17 2015-12-30 The Research Foundation For The State University Of New York Ship inhibition to induce expression of granulocyte colony stimulating factor in a subject
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CN107074975A (en) 2014-08-28 2017-08-18 生物蛋白有限公司 Condition active chimeric antigen receptor for the T cell of modification
EP3189152A4 (en) 2014-09-03 2018-04-04 BioAtla LLC Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
EP3191507A1 (en) 2014-09-09 2017-07-19 Unum Therapeutics Chimeric receptors and uses thereof in immune therapy
CA2963091A1 (en) 2014-10-06 2016-04-14 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
CN113230384A (en) 2014-10-09 2021-08-10 丹娜法伯癌症研究院 Multiple-variable IL-2 dosage regimen for treating immune disorders
TWI595006B (en) 2014-12-09 2017-08-11 禮納特神經系統科學公司 Anti-pd-1 antibodies and methods of use thereof
CA2977532A1 (en) 2015-03-06 2016-09-15 Dana-Farber Cancer Institute, Inc. Pd-l2 biomarkers predictive of pd-1 pathway inhibitor responses in esophagogastric cancers
US20180071380A1 (en) 2015-03-20 2018-03-15 The Regents Of The University Of Michigan Immunogenic compositions for use in vaccination against bordetella
US9758575B2 (en) 2015-04-06 2017-09-12 Yung Shin Pharmaceutical Industrial Co. Ltd. Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
BR112017019785B1 (en) 2015-04-13 2022-11-16 Pfizer Inc BISPECIFIC ANTIBODY, ITS USE AND PHARMACEUTICAL COMPOSITION
BR112018001202A2 (en) 2015-07-21 2018-09-25 Dyax Corp monoclonal antibody, nucleic acid, vector, host cell, pharmaceutical composition and method
WO2017015334A1 (en) 2015-07-21 2017-01-26 Saint Louis University Compositions and methods for diagnosing and treating endometriosis-related infertility
WO2017015619A1 (en) 2015-07-23 2017-01-26 The Regents Of The University Of California Antibodies to coagulation factor xia and uses thereof
MY195443A (en) 2015-08-19 2023-01-21 Pfizer Tissue Factor Pathway Inhibitor Antibodies and uses Thereof
PT3350220T (en) 2015-09-15 2021-08-06 Scholar Rock Inc Anti-pro/latent-myostatin antibodies and uses thereof
CN108431214B (en) 2015-10-05 2022-03-01 美国政府(由卫生和人类服务部的部长所代表) Human rotavirus G9P [6] strain and use as vaccine
CN108290939B (en) 2015-10-16 2023-01-13 纽约市哥伦比亚大学理事会 Compositions and methods for inhibiting lineage specific antigens
WO2017066561A2 (en) 2015-10-16 2017-04-20 President And Fellows Of Harvard College Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
US10138298B2 (en) 2015-10-23 2018-11-27 The Regents Of The University Of California Anti-IL-2 antibodies and compositions and uses thereof
WO2017075037A1 (en) 2015-10-27 2017-05-04 Scholar Rock, Inc. Primed growth factors and uses thereof
CA3002676A1 (en) 2015-10-29 2017-05-04 Dana-Farber Cancer Institute, Inc. Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids
CN106699889A (en) 2015-11-18 2017-05-24 礼进生物医药科技（上海）有限公司 PD-1 resisting antibody and treatment application thereof
BR112018013407A2 (en) 2015-12-30 2018-12-18 Kodiak Sciences Inc antibodies and conjugates thereof
TW201936640A (en) 2016-01-21 2019-09-16 美商輝瑞股份有限公司 Antibodies specific for epidermal growth factor receptor variant III and their uses
US20210309965A1 (en) 2016-03-21 2021-10-07 Dana-Farber Cancer Institute, Inc. T-cell exhaustion state-specific gene expression regulators and uses thereof
JP7099967B2 (en) 2016-07-01 2022-07-12 リサーチ ディベロップメント ファウンデーション Elimination of Proliferative Cells from Stem Cell-Derived Grafts
AU2017332721B2 (en) 2016-09-20 2023-11-09 Sara BUHRLAGE Compositions and methods for identification, assessment, prevention, and treatment of AML using USP10 biomarkers and modulators
WO2018080573A1 (en) 2016-10-28 2018-05-03 Massachusetts Institute Of Technology Crispr/cas global regulator screening platform
US20190345501A1 (en) 2017-02-07 2019-11-14 Massachusetts Institute Of Technology Methods and compositions for rna-guided genetic circuits
EP3589657A1 (en) 2017-03-03 2020-01-08 Rinat Neuroscience Corp. Anti-gitr antibodies and methods of use thereof
US20200056190A1 (en) 2017-03-16 2020-02-20 Pfizer Inc. Tyrosine prototrophy
EP3610010A4 (en) 2017-04-14 2021-02-24 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof
MX2019014465A (en) 2017-06-02 2020-01-23 Pfizer Antibodies specific for flt3 and their uses.
AU2018284077B2 (en) 2017-06-13 2021-09-23 Bostongene Corporation Systems and methods for identifying responders and non-responders to immune checkpoint blockade therapy
CN110997002A (en) 2017-07-13 2020-04-10 麻省理工学院 Targeting HDAC2-SP3 complexes to enhance synaptic function
WO2019016784A1 (en) 2017-07-21 2019-01-24 Universidade De Coimbra Anti-nucleolin antibody
US20210206882A1 (en) 2017-08-01 2021-07-08 Ab Studio Inc. Bispecific antibodies and uses thereof
WO2019070161A2 (en) 2017-10-04 2019-04-11 Opko Pharmaceuticals, Llc Articles and methods directed to personalized therapy of cancer
MX2020005364A (en) 2017-11-24 2020-08-13 Eucure Beijing Biopharma Co Ltd Anti-ox40 antibodies and uses thereof.
JP2021511811A (en) 2018-02-01 2021-05-13 ファイザー・インク CD70-specific antibodies and their use
WO2019152742A1 (en) 2018-02-01 2019-08-08 Pfizer Inc. Chimeric antigen receptors targeting cd70
WO2019165114A1 (en) 2018-02-21 2019-08-29 The University Of Montana Diaryl trehalose compounds and uses thereof
EP3755716A4 (en) 2018-02-23 2021-08-04 Eucure (Beijing) Biopharma Co., Ltd Anti-pd-1 antibodies and uses thereof
WO2019166946A1 (en) 2018-02-28 2019-09-06 Pfizer Inc. Il-15 variants and uses thereof
US11572381B2 (en) 2018-03-02 2023-02-07 The University Of Montana Immunogenic trehalose compounds and uses thereof
TWI816396B (en) 2018-05-23 2023-09-21 美商輝瑞大藥廠 Antibodies specific for gucy2c and uses thereof
MX2020012539A (en) 2018-05-23 2021-02-16 Pfizer Antibodies specific for cd3 and uses thereof.
WO2020014974A1 (en) 2018-07-20 2020-01-23 Eucure (Beijing) Biopharma Co., Ltd Anti-cd40 antibodies and uses thereof
BR112021003670A2 (en) 2018-08-28 2021-05-18 Vor Biopharma, Inc. genetically modified hematopoietic stem cells and their uses
CA3110006A1 (en) 2018-09-12 2020-03-19 Eucure (Beijing) Biopharma Co., Ltd Anti-tnfrsf9 antibodies and uses thereof
CA3116564A1 (en) 2018-11-19 2020-05-28 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-pd-1 antibodies and uses thereof
MX2021014353A (en) 2019-05-23 2022-02-21 The Univ Of Montana Vaccine adjuvants based on tlr receptor ligands.
WO2021028726A2 (en) 2019-07-03 2021-02-18 Bostongene Corporation Systems and methods for sample preparation, sample sequencing, and sequencing data bias correction and quality control
US20240050529A1 (en) 2019-10-07 2024-02-15 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021072244A1 (en) 2019-10-11 2021-04-15 Beth Israel Deaconess Medical Center, Inc. Anti-tn antibodies and uses thereof
EP4093426A1 (en) 2020-01-24 2022-11-30 University of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
WO2021205325A1 (en) 2020-04-08 2021-10-14 Pfizer Inc. Anti-gucy2c antibodies and uses thereof
WO2021224850A1 (en) 2020-05-06 2021-11-11 Crispr Therapeutics Ag Mask peptides and masked anti-ptk7 antibodies comprising such
CA3189590A1 (en) 2020-07-17 2022-01-20 Pfizer Inc. Therapeutic antibodies and their uses
CA3190227A1 (en) 2020-07-30 2022-02-03 Pfizer Inc. Cells having gene duplications and uses thereof
WO2022086852A2 (en) 2020-10-19 2022-04-28 Dana-Farber Cancer Institute, Inc. Germline biomarkers of clinical response and benefit to immune checkpoint inhibitor therapy
WO2022104104A2 (en) 2020-11-13 2022-05-19 Dana-Farber Cancer Institute, Inc. Personalized fusion cell vaccines
WO2022120256A2 (en) 2020-12-04 2022-06-09 Bostongene Corporation Hierarchical machine learning techniques for identifying molecular categories from expression data
WO2022159793A2 (en) 2021-01-25 2022-07-28 Dana-Farber Cancer Institute, Inc. Methods and compositions for identifying neuroendocrine prostate cancer
US20220372580A1 (en) 2021-04-29 2022-11-24 Bostongene Corporation Machine learning techniques for estimating tumor cell expression in complex tumor tissue
WO2022261183A2 (en) 2021-06-08 2022-12-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
CA3227875A1 (en) 2021-08-02 2023-02-09 Pfizer Inc. Improved expression vectors and uses thereof
WO2023049933A1 (en) 2021-09-27 2023-03-30 Sotio Biotech Inc. Chimeric receptor polypeptides in combination with trans metabolism molecules that re-direct glucose metabolites out of the glycolysis pathway and therapeutic uses thereof
WO2023091909A1 (en) 2021-11-16 2023-05-25 Sotio Biotech Inc. Treatment of myxoid/round cell liposarcoma patients
WO2023097119A2 (en) 2021-11-29 2023-06-01 Dana-Farber Cancer Institute, Inc. Methods and compositions to modulate riok2
US20230245479A1 (en) 2022-01-31 2023-08-03 Bostongene Corporation Machine learning techniques for cytometry
WO2023148598A1 (en) 2022-02-02 2023-08-10 Pfizer Inc. Cysteine prototrophy
WO2023158732A1 (en) 2022-02-16 2023-08-24 Dana-Farber Cancer Institute, Inc. Methods for decreasing pathologic alpha-synuclein using agents that modulate fndc5 or biologically active fragments thereof
US20240029884A1 (en) 2022-07-15 2024-01-25 Bostongene Corporation Techniques for detecting homologous recombination deficiency (hrd)
WO2024040207A1 (en) 2022-08-19 2024-02-22 Sotio Biotech Inc. Genetically engineered natural killer (nk) cells with chimeric receptor polypeptides in combination with trans metabolism molecules and therapeutic uses thereof
WO2024040208A1 (en) 2022-08-19 2024-02-22 Sotio Biotech Inc. Genetically engineered immune cells with chimeric receptor polypeptides in combination with multiple trans metabolism molecules and therapeutic uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5931799A (en) * 1982-08-16 1984-02-20 Science & Tech Agency Recombinant plasmid and preparation of transformed yeast and hepatitis virus b surface antigen using the same
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
GR862412B (en) * 1985-09-25 1987-01-23 Oncogen Vaccines and immuinoassays for acquired immune deficiency syndrome
DK3687A (en) * 1986-01-06 1987-07-07 Hoffmann La Roche POLYPEPTIDES AND PROCEDURES FOR PRODUCING THEREOF
AU1391888A (en) * 1987-02-11 1988-09-14 Scripps Clinic And Research Foundation Retroviral expression vectors and methods for producing hbv antigens
IL90048A0 (en) * 1988-04-25 1989-12-15 Merck & Co Inc Recombinant gag precursor of hiv,its preparation and its use as aids vaccine

Also Published As

Publication number Publication date
AP8900126A0 (en) 1989-07-31
ZA894137B (en) 1990-06-27
PT90731A (en) 1989-12-29
AP129A (en) 1991-04-17
AU627465B2 (en) 1992-08-27
EP0345242A3 (en) 1990-05-30
WO1991000904A1 (en) 1991-01-24
IL90381A0 (en) 1989-12-15
AU4320689A (en) 1991-02-06
EP0345242A2 (en) 1989-12-06
NZ229297A (en) 1992-01-29

Similar Documents

Publication Publication Date Title
AU4320689A (en) Expression of retrovirus gag protein in eukaryotic cells
AU4403689A (en) Hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids
AU3069189A (en) Retroviral packaging cell lines and processes of using same
AU599091B2 (en) Expression and purification of an htlv-iii gag/env gene protein
AU585180B2 (en) Nor-statine and nor-cyclostatine polypeptides
AU7184487A (en) Human g-csf protein expression
GB8817997D0 (en) Enzyme electrodes & improvements in manufacture thereof
AU4636589A (en) Tissue culture antiviral processes and compositions
AU2783989A (en) Immortalized human cell lines
AU3114489A (en) Hammermill
AU3745589A (en) Peptides having t cell helper activity
AU6399786A (en) Polypeptides used in the diagnosis and therapy of AIDS
AU3170089A (en) Mutated hiv envelope protein
NZ224667A (en) Stable human cell lines expressing foreign gene under hiv ltr regulatory control
AU7270387A (en) Enhanced expression of human interleukin-2 in mammalian cells
AU2157888A (en) Novel hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids
AU3006789A (en) Expression of hiv binding proteins
AU4257789A (en) Electro-insertion of proteins into animal cell membranes
AU2818289A (en) Electrochemical cells
AU8891691A (en) Human proteins having anticoagulant and anti-inflammatory activity
AU3836489A (en) Treatment of immunodeficiency
AU2579688A (en) Expression of hiv proteins in e. coli and s. cerevisiae
AU3625589A (en) Htlv-i / hiv-1 fusion proteins
IE891750L (en) Expression of retrovirus gag protein in eukaryotic cells
AU1996388A (en) Proteins and protein compositions and their use